Lexicon Pharmaceuticals Financial Ratios
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Lexicon Pharmaceuticals ratio analysis
Lexicon Pharmaceuticals earned a net margin of -101.1% in FY 2025, up from -644.8% a year earlier. Gross margin was 99.4% compared with a median of 98.0% over the prior 9 years. Return on equity reached -46.8%, meaning Lexicon Pharmaceuticals generated -0.47 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.50 versus 0.69 the year before, and the current ratio was 4.88. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Lexicon Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | — | — | 3.40 | — | — | — |
| Price / sales | 8.31 | 8.13 | 281.00 | 2,277.34 | 1,925.73 | — | — | 12.09 | 11.34 | 18.12 |
| Price / book | 3.85 | 1.73 | 3.63 | 2.70 | 5.05 | — | — | — | 15.23 | 8.58 |
| Gross margin | 99.4% | 98.0% | 92.9% | 100.0% | 100.0% | 92.0% | 99.0% | 96.1% | 97.9% | 100.0% |
| Operating margin | -98.2% | -634.2% | -14,265.0% | -72,489.2% | -29,224.8% | -199.2% | 43.9% | -163.4% | -142.5% | -160.5% |
| Net margin | -101.1% | -644.8% | -14,710.9% | -73,341.0% | -29,449.0% | -244.1% | 40.4% | -190.7% | -134.1% | -165.8% |
| Free cash flow margin | -136.2% | -578.5% | -13,485.6% | -64,875.5% | -29,610.1% | -596.2% | 35.3% | -235.3% | -202.4% | -221.9% |
| Return on equity (ROE) | -46.8% | -137.3% | -190.2% | -87.0% | -77.3% | -37.5% | 111.1% | — | -180.2% | -78.5% |
| Return on assets (ROA) | -27.2% | -67.2% | -77.2% | -52.5% | -64.1% | -28.7% | 31.2% | -42.4% | -28.2% | -27.6% |
| Debt / equity | 0.50 | 0.69 | 1.07 | 0.41 | 0.00 | 0.07 | 2.09 | — | 3.60 | 0.61 |
| Current ratio | 4.88 | 5.44 | 5.60 | 6.08 | 4.02 | 3.37 | 5.17 | 4.72 | 3.05 | 2.17 |
| Revenue growth | 60.2% | 2,481.5% | 766.2% | -53.4% | -98.8% | -92.5% | 409.5% | -31.1% | 15.7% | -39.0% |
| EPS growth | — | — | — | — | — | -145.7% | — | — | — | — |